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Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder which commonly affects the nervous 
system. It affects around 130:100,000 people in 
the United States.1 Females are affected 7 times 
more than males.2 In the United States, African 
American, Hispanic, and Asian populations are 
most commonly affected.1 The overall survival 
of SLE patients has significantly improved over 
the last 50 years, from 74.8 to 94.8% and from 
63.2 to 91.4% for 5-year and 10-year survival, 
respectively.3 Recent data has suggested that both 
renal and neuropsychiatric involvement negatively 
affects the overall 5-year survival rate, whereas the 
neuropsychiatric involvement did not change for 
the 10-year survival rate.3
The involvement of the nervous system is due 
primarily to the disease process, secondarily, to 
infection, or metabolic or drug-related effects. 
The aim of this review is to discuss the clinical 
picture, pathogenesis, evaluation, and treatment of 
neuropsychiatric SLE.
Clinical Picture and 
Epidemiology
The American College of Rheumatology (ACR) 
diagnostic criteria for SLE includes only psychosis 
and seizures as nervous system manifestations. 
In spite of this, different neuropsychiatric 
manifestations are recognised in patients with SLE. 
Because of the variable presentation, in 1999 the 
ACR established 19 different neuropsychiatric SLE 
syndromes (NPSLE). The classification of NPSLE 
takes into consideration the part of the nervous 
system that is affected—the central or the peripheral 
nervous system [Table 1]. The prevalence of NPSLE 
varies from 40.3% to 91.0%.4–6 The difference in the 
reported prevalence depends on the case definition 
used and the use of formal neuropsychological 
testing for patient evaluation. 
Recent data show that NPSLE affects the central 
nervous system in around 93.1% of patients and 
the peripheral nervous system in 6.9% of patients.4 
Diffuse NPSLE accounted for 79% of the events and 
only 21% were focal in nature.4 Most patients will 
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have one neuropsychiatric event, while only 17.4% 
of the patients have two or more events.4 Around 
24% of nervous system involvement occurs as an 
initial presentation.7 In general, around 50–60% of 
NPSLE occurrs at disease onset or within the first 5 
years after SLE onset.8
The reported prevalence of specific 
NPSLE is as follows: headache (47.1–57%), seizure 
(7.5–16%), cerebrovascular disease (4.7–17%), 
and polyneuropathy (2.4–22%).4–7 The prevalence 
of cognitive impairment ranges from 5.1–81%, 
depending on the study.4–6 The same observation has 
been noted for mood disorders, with the prevalence 
ranging from 16.5–51%.4,6 The major difference 
that contributes to this finding is the screening 
modality in each study. In studies where patients 
were screened with formal neuropsychiatric and 
sensitive psychiatric testing, the prevalence of 
mood disorder and cognitive impairment was high. 
Mild cognitive impairment was the most frequent 
abnormality among these patients, with only 3–5% 
exhibiting severe cognitive impairment.8 Other 
NPSLE syndromes are rarer. For example, the 
reported prevalence for movement disorders and 
transverse myelitis is around 1% in each case.
In comparison to Western data, NPSLE was 
uncommon in the data from the Arab Gulf region. 
The reported prevalence was around 15.6–19%.9-10 
In those studies, seizures were reported in 10% of 
cases, whereas the incidence of stroke ranged from 
4–11%.9-10 The other reported NPSLE syndromes 
were movement disorders, myelitis, neuropathy, 
and psychosis. The low prevalence of NPSLE in 
these data is related to the case definition used. In 
these two studies, there were no reports of cognitive 
impairment or mood disorders, both of which are 
considered common NPSLE syndromes in the data 
where higher prevalence is reported. There has 
been no specific study done in the region looking 
specifically for the prevalence of NPSLE syndromes. 
Different risk factors are associated with the 
development of NPSLE. Patients with generalised 
disease activity, prior history, or concurrent NPSLE, 
as well as those with antiphospholipid antibodies 
are at higher risk of developing NPSLE. Skin lesions 
were the most frequently reported disease activity 
in association with nervous system involvement.
Pathogenesis
Several pathophysiological mechanisms have been 
implicated in the pathogenesis of NPSLE. These 
include vasculopathy, autoantibodies, blood brain 
barrier and the cytokine effect [Table2].
In post-mortem studies, vascular occlusion 
is universally found. The most common findings 
on pathological examinations were multiple 
infarct, cortical atrophy, microhaemorrhages, and 
gross infarction. The most commonly reported 
vasculopathy is small vessel non-inflammatory 
vasculopathy.11 In several autopsy case reports 
of patients who died during an acute lupus flare, 
small vessel occlusions were secondary to leukocyte 
aggregates in the absence of immune complex 
deposition. This was most likely secondary to 
complement activation that resulted in increased 
leukocyte adhesiveness to the subendothelial 
Table 1: Neuropsychiatric syndromes associated with 
systemic lupus erythematosus
NPSLE associated with 
the central nervous 
system
NPSLE associated with 
the peripheral nervous 
system
Aseptic meningitis Acute inflammatory 
demyelinating
Cerebrovascular disease Syndromes (Guillain-Barré 
syndrome)
Demyelinating syndromes Autonomic neuropathy












NPSLE = neuropsychiatric systemic lupus erythematosus.
Table 2: Pathogenic mechanisms in neuropsychiatric 
systemic lupus erythematosus





Cytokines Promotion of antibodies production
Recruitment of immune cells
Alteration of blood brain barrier
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meta-analysis of the utility of anti-ribosomal P 
antibodies in the diagnosis of NPSLE or for specific 
NPSLE did not find a significant relation between 
them.25
Proinflammatory cytokines and chemokines also 
play a role in the pathogenesis of NPSLE. Elevated 
levels of several cytokines, including interleukin-6 
(IL-6), IL-1, IL-8, IL-10, tumour necrosis factor-
alpha (TNF-α)-, interferon (IFN)-ϒ, monocyte 
chemotactic protein 1 (MCP-1)/CCL2, interferon 
gamma-inducible protein 10 (IP-10)/CXCL10, and 
fractalkine (CX3CL1) have been found in the CSF of 
patients with NPSLE.26 They have different effects, 
including the promotion of intrathecal antibody 
production, immune cell recruitment, affecting the 
blood-brain barrier permeability by modifying the 
neuroendocrine response, and neurotransmitter 
release.27
Evaluation
When dealing with SLE patients with neurological 
presentation, careful assessment is necessary to 
exclude other potential causes [Table 3]. A detailed 
medical history, past history and medication review 
are mandatory. Laboratory evaluation is required 
to rule out secondary causes, such as infection and 
metabolic abnormalities. There is no gold standard 
diagnostic test for NPSLE. In general, the diagnostic 
approach will be the same as for non-SLE patients. 
Different diagnostic tests can be helpful when 
assessing patients with possible NPSLE. The use of 
different tests should be individualised according 
to the patient's presentation. An examination of 
CSF is indicated when infection is suspected. To 
date, there is no role for CSF autoantibody testing. 
It remains mainly of research interest. 
In the presence of focal deficit, neuroimaging is 
indicated. Magnetic resonance imaging (MRI) can 
assist with the diagnosis of cerebrovascular disease 
[Figure 1], transverse myelitis, and demyelinating 
syndromes. It is also required in patients presenting 
with seizure, acute confusional states, or movement 
disorders. An MRI scan will help to exclude other 
causes of neurological impairment, for example, 
progressive multifocal leukoencephalopathy.
In general, most reported abnormalities on MRI 
are white matter lesions and cerebral atrophy.28–30 
Advanced imaging modalities might be beneficial 
in patients with normal MRI results.  Magnetic 
surface of the blood vessels.11–13
Multiple autoantibodies have been reported 
in association with NPSLE. The most frequently 
reported antibodies are antiphospholipid anti-
bodies, a subset of anti-double-stranded DNA 
(dsDNA) and anti-ribosomal antibodies. The 
autoantibodies either obtain access to the nervous 
system through the permeable blood brain barrier 
or through direct intrathecal production.14 
Antiphospholipid antibodies are a group of 
antibodies that target the phospholipid binding 
protein, therefore altering the expression and 
secretion of procoagulants and promoting 
thrombosis. They have been associated with different 
NPSLE syndromes, including stroke, epilepsy. 
transverse myelitis, and cognitive impairment.15–18 
The pattern of cognitive impairment was consistent 
with subcortical deficit.19
N-methyl-D-aspartate (NMDA) receptors are 
glutamate receptors, which are present throughout 
brain tissue. A subset of anti-dsDNA antibodies 
were found to react with the NR2 subunit of NMDA 
receptors, which are present in the amygdala 
and hippocampus. In animal models, anti-NR2 
receptors antibodies induced apoptotic cell death 
of the hippocampus and amygdala in the presence 
of permeable blood brain barrier.20–22 In human 
studies, in which both serum and cerebrospinal 
(CSF) levels of anti-NR2 receptors correlated with 
NPSLE, no relation between NPSLE and the serum 
level was found. In contrast, a significant relation 
was found between diffuse NPSLE and CSF anti-
NRS, but none with focal NPSLE or peripheral 
NPSLE.23
Anti-ribosomal P antibodies cross-react with a 
protein on neuronal membrane, initiating apoptotic 
cell death.24 The role of anti-ribosomal P antibodies 
in the pathogenesis of NPSLE is controversial. A 
Table 3: Secondary causes of nervous system 
involvement in systemic lupus erythematosus patients
Infection
Hypertension 
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resonance spectroscopy (MRS) has shown 
neurometabolic abnormalities during both active 
and quiescent NPSLE.29 
Different neurophysiological studies can be 
beneficial in the diagnosis of subsets of NPSLE 
syndromes. In patients presenting with seizure, an 
electroencephalogram (EEG) will help to identify 
those at high risk of seizure recurrence. In patients 
presenting with acute confusional state, an EEG 
study is required to rule out the presence of seizure 
disorder. 
Nerve conduction studies (NCS) and 
electromyography (EMG) are indicated in 
patients presenting with symptoms of peripheral 
nervous system involvement. These examinations 
can help diagnose different types of neuro-
pathy (mononeuropathy versus polyneuropathy/ 
demyelinating versus axonal), plexopathy, and 
neuromuscular disorders. 
Management
The management of patients with NPSLE consists 
of correcting the aggravating factors, providing 
symptomatic treatment, and applying specific 
measures related to the disease process. One should 
try to identify and correct possible aggravating 
factors, which include metabolic or blood pressure 
abnormalities, and possible offending drugs.
Symptomatic treatment will be required 
depending on the nature of NPSLE, and it may 
be initiated before disease-specific therapy. 
Symptomatic treatment for patients with NPSLE 
is similar to symptomatic treatment of the same 
condition in non-SLE patients. This includes 
antipsychotic treatment for psychosis, antiepileptic 
treatment for patients with seizure conditions, and 
antidepressants for patients with depression.
The severity and nature of the underlying 
neurological manifestation will direct the treatment 
decision. Some patients with mild forms will only 
require symptomatic treatment such as in the case 
of patients with headaches. In 2010, the European 
League against Rheumatism (EULAR) developed 
recommendations for the management of NPSLE. 
The treatment of NPSLE depends on whether the 
process is more likely secondary to an inflammatory 
or thrombotic process.8
In inflammatory processes like transverse 
myelitis, peripheral neuropathy, refractory seizures, 
or psychosis, treatment with immunosuppressive 
therapy is indicated. Treatment should include 
glucocorticoids with or without more potent 
immunosuppressive treatment for maintenance. 
The most commonly used immunosuppressive 
therapy includes azathioprine and 
cyclophosphamide. In cases of poor response or 
failure of conventional treatment, other modalities 
can be used like plasma exchange, intravenous 
immunoglobulin, or rituximab.
In severe cases like transverse myelitis, early 
treatment with glucocorticoids in combination with 
cyclophosphamide can provide a better outcome 
than glucocorticoids alone.31 The combination 
of three modalities comprising glucocorticoids, 
cyclophosphamide, and plasma exchange has been 
used in severe cases of transverse myelitis.32–35 In 
the presence of antiphospholipid antibodies, the use 
of antiplatelets/anticoagulants can be considered in 
addition to immunosuppressive therapy.32,34
Rituximab is an anti-CD20 antibody that targets 
the B-cell directly. It induces antibody-dependent 
cellular cytotoxicity and complement-dependent 
cytotoxicity and apoptosis. Data on the use of 
rituximab in NPSLE are mostly derived from case 
reports and open-labelled studies. Tokunaga et 
al. reported 10 patients with severe NPSLE who 
failed to achieve improvements with conventional 
treatment modalities but had favourable outcomes 
with rituximab treatment.36 In their series, all 
of the treated patients showed improvement in 
their neurological statuses. A recent randomised 
controlled trial evaluated the efficacy of rituximab 
Figure 1: Diffusion-weighted image in a 50-year-old 
male patient with systemic lupus erythematosus and 




should be individualised according to the patients’ 
conditions.
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